Extreme Chronic Undervalue, page-48

The stylish Dr Ben Ellingston said our drug worked in all patients in the Phase 1 trial Artist......maybe take it up with him.

Anyway it is going to be hard to deal now because of their market cap.....under different management, an effort could be made to bring the drug to market, independent of the involvement of BigPharma.

I do not recommend or hope  the company would contemplate that (please no) ....they are not up to it and there would be more 40 cent raising.

This drug could be 100% sold into the Asia market...thus avoiding more CR over the next 3 years. FDA and EU approvals does not mean that the drug works in Asian populations, where separate trials must take place. There are in fact, dozens of studies into PI3k inhibition by China Universities. Other small companies such as MEI Pharma have taken this approach....this is a very valuable drug and an Asian deal would be very likely.

KAZIA is in a unique and enviable position (believe it or not).....in that all these big US institutions are paying for late stage trials.

They would of had about 100 patients go through Brain Metasteses Clinical Trials.... eg Dana Farber and ALLIANCE - that is probably enough  to make an approach to the FDA for early approval, by late next year.  It might only take another $20m over the next three years to get to the point of FDA approval.....what reward would then be forthcoming for aussie investors.

Other changes to the way ASX disclosures are made, would also be required.......but no, from what we have seen over the last 5 years, it is important that the drug be licensed out to avoid more dilution and a deadpan  SP, if indeed, around that $60M can be delivered.